• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Research Briefing on 4-[3,5-Bis(trifluoromethyl)phenyl]iodobenzene (CAS: 886762-46-5) in Chemical Biology and Pharmaceutical Applications

4-[3,5-Bis(trifluoromethyl)phenyl]iodobenzene (CAS: 886762-46-5) is a highly specialized organoiodine compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its trifluoromethyl-substituted phenyl ring and iodine moiety, serves as a critical building block in the synthesis of complex molecules, particularly in the development of novel therapeutics and diagnostic agents. The unique electronic and steric properties imparted by the trifluoromethyl groups make this compound an invaluable tool in modern synthetic chemistry.

Recent studies have highlighted the role of 4-[3,5-Bis(trifluoromethyl)phenyl]iodobenzene in palladium-catalyzed cross-coupling reactions, such as the Suzuki-Miyaura and Heck reactions, which are pivotal in the construction of biaryl systems. These reactions are extensively employed in the synthesis of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The compound's ability to act as an efficient arylating agent has been demonstrated in the synthesis of several drug candidates, including those targeting kinase inhibition and G-protein-coupled receptors (GPCRs).

In the context of chemical biology, 4-[3,5-Bis(trifluoromethyl)phenyl]iodobenzene has been utilized as a radiolabeling precursor for positron emission tomography (PET) imaging agents. The iodine atom can be readily substituted with fluorine-18, a positron-emitting isotope, enabling the synthesis of radiotracers for in vivo imaging of biological targets. This application is particularly relevant in oncology, where PET imaging plays a crucial role in tumor detection and treatment monitoring. Recent preclinical studies have reported the successful incorporation of this compound into radiolabeled probes for imaging amyloid plaques in Alzheimer's disease.

The pharmacokinetic and toxicological profiles of derivatives containing the 4-[3,5-Bis(trifluoromethyl)phenyl]iodobenzene moiety have been investigated in several recent studies. Researchers have noted that the trifluoromethyl groups enhance metabolic stability and membrane permeability, which are desirable properties for drug candidates. However, challenges remain in optimizing the balance between lipophilicity and solubility, as excessive fluorination can lead to poor aqueous solubility. Computational modeling and structure-activity relationship (SAR) studies are ongoing to address these limitations.

From a synthetic chemistry perspective, recent advancements have focused on developing more sustainable and efficient methods for the preparation of 4-[3,5-Bis(trifluoromethyl)phenyl]iodobenzene. Traditional routes involving hazardous reagents are being replaced by catalytic methodologies that reduce waste generation and improve atom economy. Notably, a 2023 study published in the Journal of Organic Chemistry demonstrated a copper-catalyzed iodination protocol that achieves high yields with minimal byproduct formation.

In conclusion, 4-[3,5-Bis(trifluoromethyl)phenyl]iodobenzene (CAS: 886762-46-5) continues to be a compound of significant interest in both academic and industrial research settings. Its applications span from medicinal chemistry to diagnostic imaging, with ongoing research efforts aimed at expanding its utility and addressing current limitations. As synthetic methodologies evolve and our understanding of structure-property relationships deepens, this compound is poised to play an increasingly important role in the development of next-generation pharmaceuticals and chemical biology tools.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)